Mural Oncology plc (MURA)
| Previous close | 3.2300 |
| Open | 3.2600 |
| Bid | 3.2700 x 200 |
| Ask | 3.3600 x 200 |
| Day's range | 3.2300 - 3.3050 |
| 52-week range | 3.1600 - 6.2500 |
| Volume | |
| Avg. volume | 183,395 |
| Market cap | 55.933M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. and DUBLIN, June 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that on June 3, the Company granted to two newly hired employees (i) non-statutory stock options to purchase an aggregate of 7,995 ordinary shares of the Company and (ii) restricted stock units with resp
- GlobeNewswire
Mural Oncology Presents Clinical Data from ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting
ARTISTRY-3 trial is being conducted to evaluate less frequent dosing of nemvaleukin alfa, Mural’s late-stage lead candidate Nemvaleukin demonstrated pharmacodynamic proof of mechanism in ARTISTRY-3 and was generally well-tolerated at all doses tested Less frequent dosing regimen, a shift from five daily infusions to two infusions per three-week cycle, is being evaluated as both a single agent and in combination with pembrolizumab in patients with cutaneous melanoma in ARTISTRY-6. Preliminary dat
- GlobeNewswire
Mural Oncology Announces First Quarter 2024 Financial Results and Provides Business Update
Mural’s lead product candidate, nemvaleukin alfa, is in two potentially registrational trials in platinum resistant ovarian cancer and mucosal melanoma, both of which are on track with readouts expected in 1H 2025 A new, less frequent IV dose of nemvaleukin is also being evaluated both as a single agent and in combination with pembrolizumab in patients with cutaneous melanoma with preliminary data readouts anticipated in 2025 In April 2024, Mural presented preclinical data on its investigational
